Management

Magnus Corfitzen has extensive experience from investing, building and growing Life Science companies in various roles including operational activities or investment responsibilities for public and private biotech and medtech companies. Magnus Corfitzen also has board experience from a number of Life Science companies. Magnus Corfitzen has previously inter alia been Investment Director at Sunstone Capital A/S and Investment Director at Vækstfonden (the Danish Growth Fund). Prior to entering the healthcare venture capital field he was a Portfolio Manager at Danske Capital with responsibility for investments into listed biotech and medtech companies and he started his career at McKinsey & Company.

M.Sc. in Mathematical Economics from the University of Aarhus, Denmark, which included studies at Harvard University, US.

Board member of Ascelia Inventive AB. CEO of Oncoral Pharma ApS.

27,180 shares and 458,856 employee stock options in Ascelia Pharma AB. Magnus Corfitzen also holds approximately 2 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia Pharma AB.

Carl Bjartmar has a long and solid track record in late-stage orphan drug development. He has previously served in senior roles at large international pharma companies such as Lundbeck, Sanofi and Genzyme, where he gained extensive experience in clinical development, in particular the development of novel therapies for rare diseases. Carl was most recently before joining Ascelia, Chief Medical Officer for the Swedish biotech company Wilson Therapeutics.

M.D. and Ph.D. from the University of Linköping.

-

17,000 shares and 153,059 employee stock options in Ascelia Pharma AB.

Kristian Borbos has extensive banking and finance experience from large listed companies as Sell-side Analyst and other advisory roles in banking to various financial positions in large corporates including treasury, financial reporting and planning and IR activities. Kristian Borbos has previously inter alia been Business Finance Manager at Novozymes, Lead Investor Relations Manager at DONG Energy and senior analyst at Danske Bank and Danske Markets.

M.Sc. in Business Administration from Lund University, Sweden.

Deputy board member of Ascelia Incentive AB.

3,400 shares and 153,059 employee stock options in Ascelia Pharma AB.

Dorthe da Graça Thrige has extensive experience in R&D and executive management at leading Swedish and Danish biotech and pharma companies such as Pharmacia, AstraZeneca and Active Biotech. Dorthe da Graça Thrige has previous experience from inter alia various positions at Active Biotech AB, including Director of Development, Head of Project Management and Head of Drug Discovery and Research Scientist at AstraZeneca.

M.Sc. in Pharmaceutical Sciences and Ph.D. in Structural Medicinal Chemistry from University of Copenhagen, Denmark.

-

15,530 shares and 152,898 employee stock options in Ascelia Pharma AB. Dorthe da Graça Thrige also holds approximately 1 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia.

Mikael Widell has more than 30 years’ experience within communications, including journalism with 14 years within financial media, e.g. Dagens Industri, and has had different positions within in-house corporate communications, e.g. AstraZeneca, Biovitrum (Sobi) and Nordic Capital as well as strategic work as a communications advisor within financial PR and IR. Mikael is a partner and co-founder of the IR/PR firm Cord Communications and is Head of Communication & IR at the main market listed company Calliditas Therapeutics.

M.A. in English from Lund University and studies in Economics at Lund University.

Board member of CordCom Consultants AB. General partner of WZ Kommunikation Kommanditbolag.

-